Percutaneous coronary intervention and GI hemorrhage: need for accurate predictors of the link to rebleeding
Patients with acute coronary syndrome (ACS) receive percutaneous coronary intervention (PCI) and dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor.1 GI bleeding (GIB) has an important impact on prognosis in unselected patients after PCI. Triple antithrombotic therapy and patient-related risk factors are predictors of GIB within 1 year of PCI.2 Antiplatelet therapy raises the risk of GIB.3 The DAPT score predicts a GIB after PCI. It examines the thrombosis and bleeding risk at 12 months or later after PCI.
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Felix W. Leung Tags: Editorial Source Type: research
More News: Angioplasty | Aspirin | Bleeding | Coronary Angioplasty | Endoscopy | Gastroenterology | Percutaneous Coronary Intervention | Thrombosis